




PHARMACEUTICAL 2022

Decibel Therapeutics Inc.
Rank 190 of 466





RealRate

PHARMACEUTICAL 2022

Decibel Therapeutics Inc. Rank 190 of 466



The relative strengths and weaknesses of Decibel Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Decibel Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Decibel Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 169%, being 91% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	164,191
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,538
Liabilities, Non-Current	1,611
Other Assets	14,675
Other Compr. Net Income	-131
Other Expenses	1,797
Other Liabilities	20,639
Other Net Income	205
Other Revenues	0
Property and Equipment	5,611
Research and Development	29,847
Selling, General and Administrative Expense	20,384

Output Variable	Value in 1000 USD
Assets	184,477
Liabilities	42,788
Expenses	52,028
Revenues	0
Stockholders Equity	141,689
Net Income	-51,823
Comprehensive Net Income	-51,888
Economic Capital Ratio	169%